The importance of early tumor shrinkage and deepness of response in assessing the efficacy of systemic anticancer treatment with metastatic colorectal cancer;Význam časné nádorové regrese a hloubky lecebné odpovědi při hodnocenf účinnosti systémové léčby metastazujícího kolorektálního karcinomu

Klinicka Onkologie

Volumn 28, Issue 2, 2015, Pages 89-93

  Holubec, L ^a,b   Liska V ^a,b   Finek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer; Deepness of response; Early tumor shrinkage; Neoplasm metastases; Recist

Indexed keywords

CANCER THERAPY; HUMAN; METASTATIC COLORECTAL CANCER; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; COLORECTAL NEOPLASMS; PATHOLOGY; SECONDARY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84929698750     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko201589     Document Type: Review

References (17)

1. Eisenhauer EA, Therasse P, Bogaerts J et al. New re-sponse evaluation criteria in solid tumors: revised RECIST guideline (version1.1). Europ J Cancer 2009; 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026.
2. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19(3): 508-515.
3. Arnold D, Hinke A, Reinacher-Schick AC et al. Waterfall plot analysis of XELOX or XELIRI with cetuximab or be- vacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group. J Clin Oncol 2008; 26 (15 Suppl): 4067.
4. Heun JM, Grothey A, Branda ME et al. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist 2011; 16(6): 859-867. doi: 10.1634/theoncologist.2011-0064.
5. Suzuki C, Blomqvist L, Sundin A et al.The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2012; 23(4): 948-954. doi: 10.1093/annonc/mdr350.
6. Piessevaux H, Buyse M, Schlichting M et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013; 31(30): 3764-3775. doi:10.1200/JC0.2012.42.8532.
7. Mansman UR, Sartorius U, Laubender PR et al. Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J Clin Oncol 2012; 30 (Suppl 34): Abstr. 427.
8. Mansman UR, Laubender PR, Sartorius U et al. Improved early prediction of individual prognosis for patients with mCRC: joint modeling of tumor shrinkage with volume data for PFS and OS. J Clin Oncol 2012; 30 (Suppl): Abstr. 3603.
9. Douillard JY, Salvatore S.Tabernero J et al. Overall survival (OS) and tumor shrinkage outcomes in partients with symptomatic/asymptomatic mCRC: data from the PRIME study. Ann Oncol 2013; 24 (Suppl 4): iv32-iv33.
10. Zhao B, Lee SM, Qi J et al. Minor response rate to predict patient survival. J Clin Oncol 2013; 31 (Suppl): Abstr. 3635.
11. Cremolini C, Loupakis F, Antoniotti C et al. Assessing tumor response beyond RECIST criteria: early tumor shrinkage (ETS) and deepness of response (DoR) in phase III TRIBE trial by the GONO group. Eur J Cancer 2013;49:S491.
12. Cremolini C, Loupakis F, Lonardi S et al. Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial. J Clin Oncol 2014; 32 (Suppl 3): Abstr. 521.
13. Modest DP, Laubender RP, Stintzing S et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial. Acta Oncol 2013; 52(5): 956-962. doi: 10.3109/0284186X.2012.752580.
14. Heinemann V, Modest D, Fischer von Weikersthal L et al. Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306). Ann Oncol 2014; 25 (Suppl 2): Abstr. 0-0030.
15. Rivera F. First-line treatment with modified FOL- FOX6 (mFOLFOX6) + panitumumab (pmab) or beva- cizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST. J Clin Oncol 2015; 33 (Suppl 3): Abstr. 660.
16. Hradeckà I, Rihova B, Horova R et al.The cost study of first-line treatment of metastatic colorectal carcinoma with bevacizumab-containing regimen in the Czech Republic. Klin Onkol 2014; 27(4): 255-260. doi: 10.14735/amko2014255.
17. Sevčikovà K, USSkovà V, Bartosovà Z et al. Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma. Klin Onkol 2014; 27(1): 38-44. doi: 10.14735/amko201438.